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Autoimmune diseases are caused by multiple genes and environmental effects. In addition, genetic
contributions and the number of associated genes differ among different diseases and ethnic pop-
ulations. Genome-wide association studies (GWAS) on rheumatoid arthritis (RA) and multiple scle-
rosis (MS) show that these diseases share many genetic factors. Recently, in addition to the major
histocompatibility complex (MHC) gene, other genetic loci have been found to be associated with
the risk for autoimmune diseases. This review focuses on the search for genetic variants that inﬂu-
ence the susceptibility to RA and MS as typical autoimmune diseases and discusses the future of
GWAS.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
Autoimmune diseases occur as a result of an immune response
against normal ‘‘self’’ antigens in healthy cells and tissues. Autoim-
mune diseases are caused by multiple genes as well as by environ-
mental factors. Concordance of most common autoimmune
diseases is generally higher for monozygotic twins than dizygotic
twins, suggesting the importance of genetic factors in these disor-
ders [1,2]. Furthermore, the genetic contributions and number of
genes associated with the risk of different diseases differ among
diseases and ethnic populations [3,4].
Many genome-wide association studies (GWAS) have been per-
formed across autoimmune diseases, including rheumatoid arthri-
tis (RA), multiple sclerosis (MS) systemic lupus erythematosus,
type I diabetes (T1D), Crohn’s disease, and others [5,6]. These stud-
ies show that autoimmune diseases share many genetic factors.
The MHC gene is an inﬂuential gene in the risk for autoimmune
diseases [7–9]. In addition to the MHC gene, many genetic loci
have recently been shown to be related to the risk for autoimmune
diseases. A particular set of alleles in the HLA-DRB1 locus on thecal Societies. Published by Elsevier
and Rheumatology, Graduate
ongo, Bunkyo-ku, Tokyo 113-
amoto).short arm of chromosome 6 (6p21.3) is associated with RA, MS,
T1D, and other diseases [9–13]. This gene encodes MHC class II
b-chain and is expressed on antigen presenting cells such as den-
dritic cells and B-cells. In particular, HLA-DRB1 alleles associated
with RA encode a ‘‘shared epitope’’ (SE), which is a conserved ami-
no acid sequence of binding sites of antigens [7]. During the 1980s
and 1990s, genome-wide linkage studies of RA indicated an asso-
ciation at the HLA locus among different ethnic groups [7,14–16]
despite the different SE allele frequencies among groups. In the
2000s, the strongest association was observed in the MHC region
in GWAS of MS [17,18]. Thus, the susceptibility of almost all clas-
siﬁed autoimmune diseases is related to MHC genes (see a catalog
of published GWAS at http://www.genome.gov/).
In the last 5 years, GWAS have been performed for different
autoimmune diseases, and HLA and many novel non-HLA genetic
risk factors for different disorders have been identiﬁed [17,19–
21]. GWAS using commercial single nucleotide polymorphisms
(SNPs) arrays are a powerful tool to detect common disease sus-
ceptibility variants. Autoimmune diseases have common or dis-
ease-speciﬁc associated genes, and some of these associations are
found in speciﬁc ethnic populations [3,19,22]. However, many ge-
netic factors for autoimmune diseases still remain to be identiﬁed.
This ‘‘missing heritability’’ has been observed in several autoim-
mune diseases [23,24]. Thus, we are still in the early stages of com-
plete discovery of genetic risk factors for different diseases. In thisB.V. Open access under CC BY-NC-ND license.
3628 A. Suzuki et al. / FEBS Letters 585 (2011) 3627–3632review, we will consider genetic research on RA and MS and the
next stage of GWAS.
2. Rheumatoid arthritis
RA is one of the most common systemic autoimmune diseases
in humans. It is characterized by inﬂammation of synovial tissues
and formation of rheumatoid pannus, which is capable of eroding
adjacent cartilage and bone and causing subsequent joint destruc-
tion. The prevalence of RA is 0.3–1.1% among those of European
ancestry and 0.1–0.5% among those of Asian ancestry [3]. The risks
of RA in monozygotic twins (kMZ) and siblings of affected individ-
uals (ksib) are increased 12- to 62-fold and 2- to 17-fold, respec-
tively [25]. Consequently, the heritability of RA is estimated to be
approximately 60% [1]. Thus, there is strong evidence regarding
the existence of genetic factors that increase the susceptibility to
RA. Indeed, HLA-DRB1 was initially identiﬁed as an RA-associated
molecule in the 1980s [7,26]. Consequently, many linkage studies
have been performed. These linkage studies demonstrated that
non-MHC genes were associated with RA; however, apparent sus-
ceptibility genes have not been identiﬁed [27].
In the 2000s, a case–control association study using SNPs
became a major strategy for determining genetic risk factors for
common diseases including autoimmune disorders. SNPs are much
higher-density genetic markers than microsatellite markers that
can be used for linkage studies. Therefore, more detailed genetic
analysis is possible for SNP-based case–control studies. This strat-
egy led to the identiﬁcation of the association of PADI4 in Asian RA
[28] and PTPN22 in European RA [29]. In the last several years,
GWAS using DNA array technologies have become widely available
at reasonable costs. As a result, more than 35 genetic regions have
been reported as RA susceptibility loci [27].2.1. HLA
The strongest genetic association in RA was observed in the HLA
region, on chromosome 6p21. This region extends over 3.6 Mb,
including MHC-class I, II, and III, and also contains many genes that
have immunoregulatory functions. In the 1970s, it was reported
that HLA-DR4 was associated with RA [30]. Subsequently, Greger-
sen et al. described that the conserved sequence of the third hyper-
variable region in HLA-DRB1, termed ‘‘SE’’, was strongly associated
with RA (Table 1). However, RA risk HLA-SE alleles differ between
ethnic groups. In a population of European ancestry, HLA-
DRB1⁄0401, 0404, and ⁄0101 were the most frequent RA risk al-
leles, whereas in an East Asian population, HLA-DRB1⁄0405 and
⁄0101 were the most frequent RA risk alleles [3,10,31]. Recently,
it was revealed that HLA-DRB1 SE-alleles were associated with
anti-citrullinated-peptide antibody (ACPA)-positive RA, not with
ACPA-negative RA [32,33]. ACPA is the most speciﬁc serologic mar-
ker for RA and one of the predictors of the severity of RA [34,35].
HLA-DRB⁄0301, which does not comprise the SE, allele are risk al-
leles for ACPA-negative RA in European populations [36,37]. The
role of DRB1⁄0901, another non-SE risk-allele in Asian populations,
in the appearance of APCA is controversial [36,38].2.2. Non-HLA genes
The recent availability of GWAS using DNA array technology led
to the identiﬁcation of the RA loci with a larger effect size than
linkage-based studies. GWAS have been conducted conﬁrming re-
sults of previous known loci; for example, HLA and the discovery of
many novel loci. We summarize conﬁrmed RA susceptibility loci in
Table 1. Below, we describe in detail conﬁrmed RA-associated
genes that were statistically signiﬁcant (P < 5  108) in GWAS.2.2.1. PTPN22
Some risk genes for RA are related to immunological function.
For example, the protein tyrosine phosphatase (PTP) non-receptor
22 (PTPN22) gene is known to inhibit the T-cell receptor signal
pathway via physical interaction with the Csk kinase. In subjects
of European ancestry, the second strongest genetic risk for RA after
HLA-DRB1 is conferred by a variant, rs2476601 (1858C/T, R620W),
in the PTPN22 gene, located on chromosome 1p13 [29,39]. This
variant is located in the interaction domain with Csk, resulting in
negative regulation of T-cell activation. It was reported that the
PTPN22 SNP is associated with many autoimmune disorders,
including T1D [40], systemic lupus erythematosus [41,42], juvenile
idiopathic arthritis [43], Hashimoto thyroiditis [44], and systemic
sclerosis [45]. However, rs2476601 is rare in Asian populations,
and no variant within the PTPN22 has been associated with Asian
RA populations [3,4].
2.2.2. PADI4
In 2003, peptidylariginine deiminase type 4 (PADI4) was identi-
ﬁed as a susceptibility gene for RA in a Japanese population [28].
PADI4 is a member of the PADI gene family and converts arginine
residue (peptidylarginine) to citrulline residue (peptidylcitrulline).
PADI4 is highly expressed in bone marrow, macrophages, neutro-
phils and monocytes [46–49]. Peptidylcitrulline is an interesting
molecule in RA, because it is an antigen of ACPA and only PADs
(translated protein from PADI genes) can provide peptidylcitrul-
lines, via modiﬁcation of protein substrates. In Asian populations,
association of PADI4 variants with RA susceptibility has been rep-
licated [50–52]; however, it has not been consistently replicated in
European populations [53–57]. Thus, ethnic differences in the sus-
ceptibility of PADI4 have been observed. One of the reasons for the
lack of association of PADI4 with RA in European populations may
be related to smoking. Recently, it was found that smoking inter-
acts with PADI4. Smoking is an environmental risk factor for RA,
and a signiﬁcant association between smoking and ACPA-positive
RA has been observed [3,58–60]. The smoking rate in Asian males
is higher than in European males [3]. Furthermore, an interaction
between smoking history and the HLA-DRB1 SE allele has induced
ACPA-positivity in RA [58]. Direct evidence supporting a link be-
tween PADI4 and smoking is indicated based on the ﬁnding of cit-
rullinated peptides in bronchoalveolar lavage cells in smokers but
not in non-smokers, in whom increased expression of PADI en-
zymes was also observed [61]. Gene–environment interaction be-
tween PADI4 polymorphisms and smoking was reported in both
European and Asian populations [62,63]. The difference in the con-
tribution of PADI4 to RA between Asians and Europeans might be
caused by the different prevalence of smoking in these ethnic
groups.
2.2.3. CD40 and TNFAIP3
In 2008, Raychaudhuri et al. identiﬁed CD40 as an RA risk loci in
European populations [39]. The associated SNP in CD40,
rs4810485, is located in intron2 and appears to be associated with
joint destruction in ACPA-positive RA patients [39,64]. CD40 is
widely expressed in immune cells, including B cells and mono-
cytes. CD40 signaling is regulated by TNF receptor-associated pro-
tein 1 (TRAF1) and tumor necrosis factor, alpha-induced protein 3
(TNFAIP3); these genes have also been identiﬁed as RA risk loci in
European populations [21,39]. There are at least three SNPs associ-
ated with RA in the TNFAIP3/OLIG3 region. These SNPs indepen-
dently affect RA susceptibility [65,66]. TNFAIP3 is also an RA risk
locus in subjects of Asian ancestry; however, CD40 is not associ-
ated with RA because rs4810485 in CD40 is a rare variant in Asian
populations [67]. Interestingly, CD40 is a susceptibility gene for MS
[68] and Graves’ disease. Thus, TRAF1, TNFAIP3, and CD40 signal-
ing pathways through NF-jB signaling have an important role in
Table 1
Genes and genetic regions identiﬁed as RA susceptibility loci with genome-wide signiﬁcant level (P < 5  108) or replicated by meta-analyses using two or more independent
studies.
Susceptibility gene Variant Authors Publish
HLA gene
HLA-DRB1 ⁄0401, ⁄0404, ⁄0101, 0405, ⁄0301, ⁄0901 Lee, H.S., et al., du Montcel, S.T., et al., Furuya, T., et al., Irigoyan, P., et al. 2004, 2005, 2007
Non-HLA gene
CTLA4 rs3087243, rs11571300 WTCCC 2007
STAT4 rs7574865 Remmer, E.F., et al. 2007
TRAF1/C5 rs3761847, rs10818488 Plenge, R.M. 2007
PTPN22 rs2476601, rs6679677 Begovich, A,B., et al., WTCCC 2004, 2007
TNFAIP3/OLIG3 rs6920220, rs5029937, rs13207033a Raychaudhuri, S., et al., Orozco, G., et al., Shimane, K., et al. 2009, 2010
IL2RB rs3218253, rs743777 WTCCC, Barton, A., et al. 2007, 2008
KIF5A/PIP4K2C rs1678542 Barton, A., et al., Raychaudhuri, S., et al. 2008, 2009
PRKCQ rs4750316 Raychaudhuri, S., et al. 2009
CD40 rs4810485 Raychaudhuri, S., et al. 2009
TNFSF14/MMEL1 rs3890745 Raychaudhuri, S., et al. 2009
AFF3 rs10865035 Barton, A., et al. 2009
IL2-IL21 rs6822844 Barton, A., et al. 2009
CCL21 rs2812378 Plant, D., et.al. 2010
PADI4 rs2240340 Suzuki, A., et al. 2003
FCRL3 rs7528684 Kochi, Y., et al. 2005
IRF5 rs3807306 Sigurdsson, S., et al. 2007
CD2/CD58 rs11586238 Raychaudhuri, S., et al. 2008
CD28 rs1980422 Raychaudhuri, S., et al. 2008
PRDM1 rs548234 Raychaudhuri, S., et al. 2008
CCR6 rs3093024, rs968334, rs3093023 Kochi, Y., et al., Stahl, E.A., et al. 2010
a Protective.
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RA.
2.2.4. CCR6
In 2010, chemokine (C–C motif) receptor 6 (CCR6) was identi-
ﬁed as an RA-associated gene in Asian and European populations
[20,69]. In particular, rs3093024 in the CCR6 gene is the second
largest genetic risk allele in a Japanese RA population. Functionally,
the CCR6 gene is an important molecule in Th17 cells, which are a
subset of helper T cells that produce IL-17. In SKG mice, an animal
model for RA, Ccr6-positive Th17 cells are recruited to the inﬂamed
joint by Ccl20, a ligand for Ccr6. Thus, CCR6 gene expression con-
tributes to Th17 cell function in RA [70]. A dinucleotide polymor-
phism, termed as CCR6DNP, in strong linkage disequilibrium
with rs3093024 was found to affect CCR6 expression level in lym-
phoblastoid cell lines. The CCRDNP genotype was also associated
with titer of IL-17 in sera of RA patients [20]. Th-17 cells, which ex-
press CCR6, are present in inﬂamed RA synovial tissue [71]. Kochi
et al. suggested that enhanced CCR6 expression by CCR6DNP leads
to the activation of Th17 cells [20].
2.3. Summary of genetic risk factors for RA
Many genes and genetic regions have been identiﬁed as RA
susceptibility loci, and associations have been conﬁrmed via inde-
pendent replication studies and meta-analysis (Table 1). Most
conﬁrmed genetic risks are related to the immune system,
although GWAS were performed under hypothesis-free condi-
tions. Therefore, it is still unclear whether each variant or a com-
bination of multiple variants contributes to the risk for
development and/or progression of RA. Interestingly, there is
apparent ethnic heterogeneity in RA, as genetic variations and
disease susceptibility genes, such as HLA-DRB1 alleles, PTPN22 al-
leles, and PADI4 alleles, have been noted in different populations.
However, little or nothing is known regarding how these genetic
risks physiologically affect the mechanism of RA development.
Further ﬁne-mapping studies including next generation sequenc-
ing and functional studies will help provide additional informa-
tion regarding genetic risks for RA.3. Multiple sclerosis (MS)
MS is an inﬂammatory autoimmune disease in which the mye-
lin sheath and spinal cord in the central nervous system are dam-
aged, resulting in demyelination and axonal loss. T-cell, B-cell, and
macrophage inﬁltration have been observed in active demyelina-
tion lesions in the brain of MS patients and spinal cord atrophy
is common [72]. The prevalence of MS in the European population
is 0.1–0.2%, whereas the prevalence in the Asian population is less
than 0.004–0.01%. kMZ of MS is 200 and ksib is 20 [13,73]. Thus,
there is stronger evidence of the heritability of MS than of RA.
In the 1970s, Terasaki et al. showed the association of HLA-
Dw2 with MS [74]. Subsequently, linkage studies revealed that
variations of HLA-DRB1 were associated with MS [12,75]. In the
last several years, several GWAS have been performed using
DNA array chips, and susceptibility genes for MS have been iden-
tiﬁed (Table 2). However, the number of MS-associated common
variants is estimated at 100, with each variant exerting only a
modest effect on risk (approximately odds ratio 1.1–1.3) [76].
Consequently, many susceptibility SNPs have still not been dis-
covered. Furthermore, recent genetic cohort studies have impli-
cated vitamin D, Epstein-Barr virus, and smoking as strong
environmental risk factors for MS [13,77].
3.1. HLA
From the 1970s to 2005, the only knownMS risk locus was HLA-
class II, and in particular, an association with HLA-Dw2 seemed to
represent the strongest risk for MS [74]. Ligers et al. showed signif-
icant evidence of linkage in the HLA-DRB1⁄15 (HLA-DRB1⁄1501
and HLA-DRB5⁄0101) gene [78]. In 2006, a family-based associa-
tion study of this HLA-class II region revealed that the HLA-
DRB1⁄15 had the strongest association with MS (P = 7.8  1031),
and a dominant dose effect was conﬁrmed [12]. In 2007, the Inter-
national Multiple Sclerosis Genetic Consortium (IMSGC) completed
the ﬁrst MS GWAS using high-resolution DNA array technology
[18]. They also conﬁrmed that rs3135391, with an SNP tagged for
HLA-DRB1⁄1501, represented the strongest association for MS
(P = 8.94  1081). Moreover, IMSGC reported ﬁne-mapping in the
Table 2
Genes and genetic regions identiﬁed as MS susceptibility loci with genome-wide signiﬁcant level (P < 5  108) or replicated by meta-analyses using two or more independent
studies.
Susceptibility gene rs number Authors Publish
HLA gene
HLA-DRB1 rs3035391(⁄1501), rs3129860 Haﬂer, D.A., et al., Baranzini, S.E., et al., Cree, B.A., et al 2007, 2009, 2010
HLA-B rs2523393 De Jager, P.L., et al. 2009
Non-HLA gene
IL2RA rs12722489, rs2104286 IMSGC 2007, 2008
IL-7RA rs6897932 IMSGC, Gregory, S.G., et al., Landmark, F., et al. 2007
CLEC16A rs6498169, rs12708716 IMSGC 2007, 2009
CD58 rs12044852, rs2300747 IMSGC, De Jager, et al. 2007, 2008
CD6 rs17824933 De Jager, P.L., et al. 2009
IRF8 rs17445836 De Jager, P.L., et al. 2009
TNFRSF1A rs1800693, rs4149584 De Jager, P.L., et al. 2009
METTL1 rs10876994, rs12368659, rs703842 ANZgene 2009
CD40 rs6074022, rs1569723 ANZgene 2009
TYK2 rs34536443 Burton, P.R., et al., WTCCC, ANZgene 2007, 2009
GPC5 rs9523762 Gene MSA 2009
STAT3 rs744166 Jakkula, E., et al. 2010
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HLA-B gene was a novel gene associated with MS; however, HLA-
B had a less strong association with MS than HLA-DRB1 [79]. Thus,
HLA-DRB1 is the most signiﬁcant gene for MS as well as RA.
3.2. Non-HLA genes
IMSGC reported the ﬁrst MS GWAS [18,80] and identiﬁed IL-
2RA as a novel susceptibility locus. Subsequently, many MS GWAS
were performed and a number of MS-associated genes have been
discovered. To date, the identiﬁed non-HLA MS risk alleles are
common in the general population, and the effect of each risk allele
is modest (odds ratio, 1.1–1.3). Conﬁrmed MS risk alleles are
shown in Table 2. We describe established MS-associated genes
(P < 5  108) below.
3.2.1. IL2RA
Except for the HLA gene, IL2RA was the ﬁrst MS-associated gene
identiﬁed by GWAS performed by IMSGC. This study highlighted
an SNP with a genome-wide signiﬁcant P-value in the alpha chain
of the interleukin-2 receptor (IL2RA) gene region: rs12722489
(P = 2.96  108) [18]. This association has been replicated in MS
subjects from Canada, Australia, and Europe [81]. Furthermore,
ﬁne-mapping was performed and showed that rs2104286 was
the most signiﬁcant SNP in the IL2RA region [81]. IL-2RA is also a
susceptibility gene for T1D [82]. The IL-2RA is one of the receptors
for IL-2, and the IL-2/IL-2RA pathway is important for regulating
the immune response. IL-2 plays a key role in expansion and apop-
tosis of T-cells, and MS-associated variants in the IL2RA gene con-
tribute to the production of soluble IL-2RA [83].
3.2.2. CLEC16A
In 2008, IMSGC identiﬁed a strong association for rs12708716
in the C-type lectin domain family 16 member A (CLEC16A) gene
on chr16p13.3 (P = 1.6  1016). The association of CLEC16A was
replicated by several studies, and CLEC16A was also shown to be
a susceptibility gene for T1D [84–86]. The function of CLEC16A is
still unknown, however. CLEC16A likely plays a role in the immune
system because CLEC16A is exclusively expressed in immune cells,
such as B lymphocytes and natural killer cells.
3.2.3. METTL1
The Australia and New Zealand Multiple Sclerosis Genetics Con-
sortium (ANZgene) identiﬁed several risk-associated SNPs, includ-
ing rs703842, in the methyltransferase-like protein 1 (METTL1)
gene (P = 5.4  1011) [68]. The most signiﬁcant SNP, rs703842, islocated in the 30 UTR of the METTL1. Handel et al. investigated
whether MS-associated SNPs correlated with gene expression.
rs703842 and other risk-associated SNPs in the METTL1 region al-
tered the expression level of a proximal gene, that is, Ts translation
elongation factor, mitochondrial (TSFM) [87]. These susceptibility
SNPs affect the expression of TSFM, and this gene is a reasonable
candidate in terms of gene expression. Further studies are needed
to clarify the functional effects of these SNPs.
3.3. Summary of genetic risk factors for MS
Recently, several GWAS were performed using DNA chip tech-
nology. This extensive screening approach led to rapid progress
in the identiﬁcation of MS-associated alleles. Based on these
GWAS, 20–30 loci have been discovered outside the HLA region.
These loci are suggested to confer an increased risk for developing
MS. MS shares CD40 as a susceptibility gene with RA. This result
assumes that common genetic mechanisms may be present in RA
and MS. Most GWAS for MS were performed in populations of
European descent. A meta-analysis with GWAS using other ethnic
groups would be useful to identify new risk alleles.
4. Shared susceptibility genes between RA and MS
Multiple GWAS have been reported in autoimmune diseases,
and many common variants have been identiﬁed. Baranzini et al.
performed a compilation of GWAS published in autoimmune dis-
eases, including RA and MS, and presented shared susceptibility
genes using a network-based analysis [88,89]. For RA and MS, a
strong cluster of genes in the MHC region was observed [88,89].
However, this may be caused by the strong linkage disequilibrium
in this genomic region [2]. RA also shared 12 non-MHC genes with
MS (1.49 expected, P = 3.4  1018), indicating statistically signiﬁ-
cant sharing between RA and MS [88]. Autoimmune diseases
including RA and MS arise when physiological tolerance to self-
antigens does not work. Indeed, co-occurrence of several autoim-
mune diseases has been observed sporadically and familiarly
[90,91]. Therefore, common pathogenic processes, for example,
abnormalities in T-cell and B-cell activation leading to inﬂamma-
tion, are suggested. The presence of shared susceptibility also sup-
ports this suggestion.
5. Missing heritability of RA and MS
To date, GWAS have identiﬁed many susceptibility polymor-
phisms with RA, MS, and other autoimmune diseases with complex
A. Suzuki et al. / FEBS Letters 585 (2011) 3627–3632 3631traits. However, a largeproportionof RAandMSheritability remains
unknown [27,92,93]. For example, the contribution of identiﬁed
non-HLA and HLA risks of RA is estimated at approximately 35%
[92]. Most common variants with an odds ratio of approximately
1.2 should be detected in GWAS using about 10 000 cases and
10 000 controls. Therefore, it is necessary to increase the sample
number for GWAS to identify novel causative genes [93]. Some of
this ‘‘missing heritability’’ is likely caused by rare variants or incom-
plete linkage disequilibrium between causal variants and tagged
SNPs [23,94]. Large-scale resequencing, like the 1000 Genome Pro-
ject (www.1000genomes.org), will be helpful in detecting rare vari-
ants that could have a stronger effect size and clarify the perfect LD.
In addition, for complete understanding of genetic risk factors, rare
genetic variation in genomes of patients will need to be detected by
next-generation sequencing technologies. Additionally, gene–gene
interaction studies using large-scale resequencing will help com-
plete our understanding of genetic predisposition to disease, and
the studyof functional effects of associatedvariants and/or its epige-
netic effects on the regulation of gene expression, protein function,
protein localization, protein structure will follow.
To understand many common diseases comprehensively,
including RA and MS, GWASmust be performed with consideration
of environmental and genetic factors and their interaction. Smok-
ing is a known environmental risk factor for RA, and smoking
and the HLA-DRB1 gene interact as risk factors for RA [58]. How-
ever, it is difﬁcult to identify all environmental factors using cur-
rent GWAS data.
6. Conclusion
Advances in GWAS allowed a large number of DNA markers to
be genotyped (>100 000 SNPs) to capture common genetic vari-
ants; large GWAS meta-analyses are currently in progress. How-
ever, these risk loci do not entirely explain the genetic
contribution to disease susceptibility, and common genetic vari-
ants do not have equal causative effects. It is more difﬁcult to iden-
tify causative variants and understand the causative gene
functions. Understanding connections between causative geno-
types and phenotypes will be important for the discovery of new
pathological mechanisms and appropriate therapies.
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